Octreotide: Clinical Overview
Primary Indications
Octreotide is FDA-approved for three specific conditions: acromegaly (in patients with inadequate response to surgery, radiation, or bromocriptine), symptomatic treatment of metastatic carcinoid tumors (for diarrhea and flushing), and VIPomas (for profuse watery diarrhea). 1
Approved Indications
- Acromegaly: Reduces growth hormone (GH) and IGF-1 levels in patients who have failed or cannot undergo surgery, pituitary irradiation, or maximally tolerated bromocriptine 1
- Carcinoid tumors: Controls severe diarrhea and flushing episodes in metastatic disease 2, 1
- VIPomas: Treats profuse watery diarrhea associated with VIP-secreting tumors 2, 3, 1
Additional Clinical Uses (Based on Guidelines)
- Glucagonomas: Improves necrolytic migratory erythema and other symptoms 3
- Carcinoid crisis prevention: Critical perioperative use in functional NETs 2, 3
- Dumping syndrome: Effective for both early and late symptoms post-gastric surgery 4
Limited or Ineffective Uses
- Gastrinomas: NOT first-line; PPIs are preferred. Use only in refractory cases 2
- Insulinomas: Often ineffective (only 50-60% have appropriate somatostatin receptors). Diazoxide is preferred at 200-600 mg/day orally 2
Dosing Regimens
Short-Acting Octreotide (Subcutaneous)
For acute symptom control and initial stabilization, start with short-acting octreotide 50-100 mcg subcutaneously 2-3 times daily, with maximum doses up to 1500 mcg/day. 3, 1
- Acromegaly: 50 mcg three times daily initially; titrate based on GH/IGF-1 levels every 2 weeks. Most patients require 100 mcg three times daily; maximum 500 mcg three times daily 1
- Carcinoid tumors: 100-600 mcg/day in 2-4 divided doses initially (mean 300 mcg/day); maintenance median ~450 mcg/day 1
- VIPomas: 200-300 mcg/day in 2-4 divided doses initially 1
- Carcinoid crisis prevention: 50 mcg/hour IV starting 12 hours before procedure, continuing during and 48 hours after 3
- Dumping syndrome: 50-100 mcg subcutaneously before meals 4
Long-Acting Formulations (Standard of Care)
Long-acting formulations should be considered the standard of care for chronic symptomatic treatment due to superior quality of life and comparable or better efficacy. 2
- Octreotide LAR: 10,20, or 30 mg intramuscularly every 4 weeks 2
- Lanreotide Autogel: 60,90, or 120 mg every 4 weeks 2
- Start with lower doses and up-titrate to achieve stabilization 2
- Therapeutic levels not achieved for 10-14 days after LAR injection 5
- For breakthrough symptoms: Add short-acting octreotide 2-3 times daily (max ~1 mg/day) OR reduce injection interval from 4 to 3 weeks 2
Transition Strategy
Stabilize patients on short-acting octreotide for 10-28 days before converting to long-acting formulations 3
Contraindications
The only absolute contraindication is hypersensitivity to octreotide or any component of the formulation. 1
Warnings and Precautions
Cardiac Function Abnormalities
Complete atrioventricular block has been reported with IV octreotide, particularly at higher than recommended doses or with continuous infusion. 1
- Bradycardia occurred in 25% of acromegalic patients 1
- Conduction abnormalities in 10%, arrhythmias in 9% 1
- Consider cardiac monitoring for IV administration 1
- Dose adjustments of beta-blockers and other bradycardia-inducing drugs may be necessary 1
Cholelithiasis
Gallbladder abnormalities occur in approximately 63% of patients on long-term therapy (27% gallstones, 24% sludge, 12% biliary duct dilatation). 1
- Incidence reaches 52% in patients treated ≥12 months 1
- Less than 2% develop stones with treatment <1 month 1
- Acute cholecystitis, ascending cholangitis, biliary obstruction, cholestatic hepatitis, or pancreatitis can occur 1
- Discontinue if complications suspected 1
- Monitor periodically with ultrasound if clinically indicated
Glucose Metabolism
Octreotide alters the balance between insulin, glucagon, and GH, potentially causing hypoglycemia or hyperglycemia. 1
- Hypoglycemia occurred in 3% of acromegalic patients 1
- Hyperglycemia occurred in 16% of acromegalic patients 1
- Post-prandial hyperglycemia with impaired insulin secretion is common 6
- Monitor glucose levels and adjust anti-diabetic medications as needed 1
- One patient in studies required oral hypoglycemic agents 6
Thyroid Function
Hypothyroidism may occur; monitor thyroid function periodically. 1
- Assess total and/or free T4 at baseline and during chronic therapy 1
Common Adverse Effects
Most Frequent (>10% incidence)
In acromegalic patients 1:
- Gallbladder abnormalities
- Sinus bradycardia
- Diarrhea/loose stools
- Nausea
- Abdominal discomfort
- Hyperglycemia
- Hypothyroidism
Other Common Side Effects
Generally mild and well-tolerated 3:
- Pain or burning at injection site
- Fat malabsorption
- Vitamin A and D malabsorption
- Headaches
- Dizziness
- Flatulence, abdominal cramps (usually abate with continued treatment) 7
- Reversible hair loss (rarely alopecia) 7
Monitoring Requirements
Acromegaly
- GH or IGF-1 levels every 2 weeks after initiation or dose change 1
- Goal: GH <5 ng/mL or IGF-1 within normal range 1
- Withdraw octreotide yearly for ~4 weeks to assess disease activity 1
Carcinoid Tumors
- Urinary 5-HIAA, plasma serotonin, plasma Substance P 1
- Echocardiogram if signs/symptoms of carcinoid heart disease 5
VIPomas
- Plasma VIP levels 1
All Patients
- Circulating and urinary hormone levels during treatment 3
- Regular imaging as clinically indicated 3
- Glucose monitoring 1
- Thyroid function tests 1
Drug Interactions
Monitor and adjust doses of the following when used with octreotide 1:
- Cyclosporine (may interfere with absorption) 8
- Insulin and oral hypoglycemic agents
- Beta-blockers
- Bromocriptine
Lutetium Lu 177 Dotatate: Discontinue octreotide at least 24 hours prior to each dose 1
Efficacy Data
Neuroendocrine Tumors
- Biochemical response (hormone inhibition): 30-70% of patients 2, 3, 2
- Symptomatic control: Majority of patients 2
- Tumor shrinkage >50%: 59% of patients 2
- Median time to tumor progression in PROMID trial: 14.3 months vs 6 months with placebo (p=0.000072) 5
Specific Syndromes
- Carcinoid syndrome: Substantial relief of flushing and diarrhea in majority 3
- VIPomas: Dramatic response with cessation of diarrhea in this life-threatening syndrome 3
- Dumping syndrome: 73% response in case series, 64% in RCTs 9
Special Considerations
Imaging Interactions
- Withdraw short-acting octreotide 24-48 hours before somatostatin receptor scintigraphy 2
- For long-acting formulations, schedule imaging toward end of dosing interval, just before next injection 2
Reproductive Potential
Advise premenopausal females of potential for unintended pregnancy 1